The U.S patent office is re-examining the patent on Merck's popular asthma treating drug , SINGULAIR. The product is worth $4.5 billion per year.
The USPTO ordered re-examination as requested by Article One Partners LLC, who are experts in identifying improperly issued patents (invalid patents).
If this patent document with actual expiry dated 2012 is invalidated, the generic drug manufacturers will pitch into the market to produce cheaper version of the drug.
No comments:
Post a Comment